Peer-reviewed veterinary case report
Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma
- Journal:
- Veterinary and Comparative Oncology
- Year:
- 2013
- Authors:
- Kozicki, A. R. et al.
- Affiliation:
- Department of Medical Sciences University of Wisconsin‐Madison Madison WI USA · United States
- Species:
- dog
Abstract
AbstractAmputation and chemotherapy are the mainstay of treatment for canine appendicular osteosarcoma (OSA).In vitrostudies have demonstrated anti‐tumour activity of pamidronate against canineOSA. The purpose of this study was to assess the safety of adding pamidronate to standard post‐operative carboplatin chemotherapy in 17 dogs with appendicularOSAtreated with limb amputation. Median disease‐free interval (DFI) and median survival time (MST) were evaluated as secondary endpoints. Incidence of side effects and treatment outcomes were compared to 14 contemporary control patients treated with carboplatin alone. There were no identified side effects to the pamidronate treatment. The medianDFIfor the study group was 185 days compared to 172 days for the control group (P= 0.90). TheMSTof the study group was 311 days compared to 294 days for the control group (P= 0.89). Addition of pamidronate to carboplatin chemotherapy for the treatment of canine appendicularOSAis safe and does not impair efficacy of standard carboplatin treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.1111/vco.12040